- Home
- IGMS vs VATE Comparison
IGMS vs VATE Comparison
Compare IGMS & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- VATE
- Stock Information
- Founded
- IGMS 1993
- VATE 1994
- Country
- IGMS United States
- VATE United States
- Employees
- IGMS N/A
- VATE N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- VATE Metal Fabrications
- Sector
- IGMS Health Care
- VATE Industrials
- Exchange
- IGMS Nasdaq
- VATE Nasdaq
- Market Cap
- IGMS 82.1M
- VATE 98.2M
- IPO Year
- IGMS 2019
- VATE 1996
- Fundamental
- Price
- IGMS $1.26
- VATE $5.45
- Analyst Decision
- IGMS Hold
- VATE
- Analyst Count
- IGMS 8
- VATE 0
- Target Price
- IGMS $6.14
- VATE N/A
- AVG Volume (30 Days)
- IGMS 172.4K
- VATE 46.0K
- Earning Date
- IGMS 05-13-2025
- VATE 05-06-2025
- Dividend Yield
- IGMS N/A
- VATE N/A
- EPS Growth
- IGMS N/A
- VATE N/A
- EPS
- IGMS N/A
- VATE N/A
- Revenue
- IGMS $2,681,000.00
- VATE $1,066,100,000.00
- Revenue This Year
- IGMS $124.45
- VATE N/A
- Revenue Next Year
- IGMS $45.07
- VATE N/A
- P/E Ratio
- IGMS N/A
- VATE N/A
- Revenue Growth
- IGMS 27.36
- VATE N/A
- 52 Week Low
- IGMS $0.92
- VATE $3.25
- 52 Week High
- IGMS $22.50
- VATE $13.79
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- VATE 41.51
- Support Level
- IGMS $1.13
- VATE $5.63
- Resistance Level
- IGMS $1.42
- VATE $8.28
- Average True Range (ATR)
- IGMS 0.09
- VATE 0.69
- MACD
- IGMS 0.01
- VATE -0.04
- Stochastic Oscillator
- IGMS 52.94
- VATE 7.21
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.